SpecificiT Pharma develops personalized hematological cancer immunotherapies by using Minor Histocompatability Antigens (MiHAs) which enable donor T-cells to be safely directed to eliminate cancer cells following allogeneic hematopoietic cell transplantation (AHCT).
SpecificiT Pharma Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.specificitpharma.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address1010 Sherbrooke Street West, Suite 408, QC, H3A 2R7MontrealCanada
1010 Sherbrooke Street West, Suite 408, QC, H3A 2R7
Montreal
Canada
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/specificit-pharma-inc” connections=”true” suffix=””]
SpecificiTs unique approach is centered on the use of Minor Histocompatability Antigens (_MiHAsÓ) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient.
In Sep 2017, SpecificiT Pharma completed seed financing by existing shareholder AmorChem, along with new partners, Sanderling Ventures and Accel-Rx Health Sciences Accelerator.